Key Points
- Insider selling: EVP Andrew Callos sold 1,042 shares on Dec. 8 at about $65.96 for $68,730 and had also sold 52,486 shares on Dec. 5 for ~$3.46M, reducing his stake to 50,660 shares (a 2.02% decrease).
- Analyst sentiment: Wall Street is broadly positive—13 Buys, 3 Holds and 1 Sell—with a consensus target of $79.29 and multiple firms recently raising price targets.
- Recent results and stock trend: Cytokinetics reported -$1.54 EPS on Nov. 5 (beating by $0.05) but revenue missed at $1.94M despite 318% YoY growth; the stock is down ~2.3%, with a market cap of ~$7.84B and a 12‑month range of $29.31–$69.33.
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 1,042 shares of the company's stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $65.96, for a total transaction of $68,730.32. Following the transaction, the executive vice president owned 50,660 shares in the company, valued at $3,341,533.60. This represents a 2.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Andrew Callos also recently made the following trade(s):
- On Friday, December 5th, Andrew Callos sold 52,486 shares of Cytokinetics stock. The stock was sold at an average price of $65.95, for a total transaction of $3,461,451.70.
Cytokinetics Stock Down 2.3%
CYTK opened at $64.13 on Tuesday. The stock has a market capitalization of $7.84 billion, a price-to-earnings ratio of -10.20 and a beta of 0.58. The firm has a 50 day moving average price of $62.13 and a 200-day moving average price of $46.71. Cytokinetics, Incorporated has a twelve month low of $29.31 and a twelve month high of $69.33.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) EPS for the quarter, topping analysts' consensus estimates of ($1.59) by $0.05. The company had revenue of $1.94 million during the quarter, compared to the consensus estimate of $6.05 million. The company's revenue for the quarter was up 318.1% on a year-over-year basis. During the same period last year, the firm posted ($1.36) EPS. As a group, analysts expect that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of analysts recently commented on CYTK shares. Stifel Nicolaus upped their price objective on Cytokinetics from $87.00 to $96.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. Evercore ISI raised their target price on Cytokinetics from $60.00 to $80.00 and gave the stock an "outperform" rating in a research report on Wednesday, September 3rd. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Cytokinetics in a research report on Tuesday, October 21st. Barclays increased their price objective on shares of Cytokinetics from $71.00 to $82.00 and gave the stock an "overweight" rating in a research note on Monday, October 6th. Finally, UBS Group restated a "neutral" rating and set a $61.00 target price on shares of Cytokinetics in a research report on Monday, December 1st. Thirteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $79.29.
Get Our Latest Stock Report on CYTK
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. Quarry LP bought a new position in shares of Cytokinetics during the 3rd quarter valued at approximately $30,000. Advisory Services Network LLC bought a new stake in Cytokinetics during the 3rd quarter worth approximately $32,000. Johnson Financial Group Inc. purchased a new position in Cytokinetics during the third quarter valued at approximately $40,000. EverSource Wealth Advisors LLC lifted its holdings in Cytokinetics by 723.7% during the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 673 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Cytokinetics in the third quarter worth approximately $45,000.
About Cytokinetics
(
Get Free Report)
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
